A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

NCT02170727 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: DCV/ASV/BMS-791325

Sponsor

Bristol-Myers Squibb